Posted by Michael Wonder on 19 Aug 2023
Eylea HD (aflibercept) 8 mg injection approved by FDA for treatment of wet age-related macular degeneration, diabetic macular oedema and diabetic retinopathy
18 August 2023 - Approval based on the pivotal PULSAR and PHOTON trials in which Eylea HD demonstrated clinically equivalent vision gains to Eylea (aflibercept) Injection 2 mg that were maintained with fewer injections.
Regeneron Pharmaceuticals today announced that the US FDA has approved EYLEA HD (aflibercept) 8 mg injection for the treatment of patients with wet age-related macular degeneration diabetic macular oedema and diabetic retinopathy.
